Aura Biosciences Inc. Company Profile
NASDAQ: AURAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 9:40 AM ET
Aura Biosciences at a glance
Aura Biosciences Inc. (NASDAQ: AURA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Boston, MA. Aura Biosciences is led by Ms. Natalie C. Holles and employs about 113 people. The company's shares have traded publicly since 2021.
At a market capitalization of $669.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001501796, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Aura Biosciences do?
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Aura Biosciences Inc.
- Ticker
- NASDAQ: AURA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Ms. Natalie C. Holles
- Employees
- 113
- Headquarters
- 80 Guest Street, Boston, MA, United States
- Phone
- 617 500 8864
- Website
- aurabiosciences.com
- IPO year
- 2021
- Market cap
- $669.93M
- SEC CIK
- 0001501796
Companies similar to Aura Biosciences
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FDMT4D Molecular Therapeutics Inc. | 12.26 | -2.66% | $677.02M | vs AURA |
| PRMEPrime Medicine Inc. | 3.77 | -3.30% | $684.01M | vs AURA |
| SLDBSolid Biosciences Inc. | 6.69 | -2.33% | $717.34M | vs AURA |
| PROKProKidney Corp. Class A | 1.55 | -1.27% | $618.73M | vs AURA |
| DBVTDBV Technologies S.A. ADR | 9.74 | -0.36% | $611.83M | vs AURA |
| DNAGinkgo Bioworks Holdings Inc. Class A | 10.90 | -4.93% | $733.67M | vs AURA |
| CADLCandel Therapeutics Inc. | 9.62 | -2.03% | $736.11M | vs AURA |
| ATTOAttovia Therapeutics Inc. | 16.20 | -1.34% | $739.55M | vs AURA |